<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="NEW YORK, NY / ACCESSWIRE / April 16, 2020 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff. There will be no obligation or cost to you.” data-reactid=”12″>NEW YORK, NY / ACCESSWIRE / April 16, 2020 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff. There will be no obligation or cost to you.
<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="VMware, Inc. (VMW)” data-reactid=”13″>VMware, Inc. (VMW)
<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/vmware-inc-loss-submission-form?prid=6053&wire=1
Lead Plaintiff Deadline: June 1, 2020
Class Period: March 30, 2019 to February 27, 2020″ data-reactid=”14″>If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/vmware-inc-loss-submission-form?prid=6053&wire=1
Lead Plaintiff Deadline: June 1, 2020
Class Period: March 30, 2019 to February 27, 2020
Allegations against VMW include that: (i) VMware’s reporting with respect to its backlog of unfilled orders was not in compliance with all relevant accounting and disclosure requirements; (ii) the foregoing subjected the Company to a foreseeable risk of heightened regulatory scrutiny and/or investigation; and (iii) as a result, the Company’s public statements were materially false and misleading at all relevant times.
<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="Gossamer Bio, Inc. (GOSS)” data-reactid=”16″>Gossamer Bio, Inc. (GOSS)
<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/gossamer-bio-inc-loss-submission-form?prid=6053&wire=1
Lead Plaintiff Deadline: June 2, 2020
Class Period: common stock between February 8, 2019 and December 13, 2019 and/or who acquired Gossamer shares pursuant or traceable to Gossamer’s documents issued in connection with its February 8, 2019 initial public offering.” data-reactid=”17″>If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/gossamer-bio-inc-loss-submission-form?prid=6053&wire=1
Lead Plaintiff Deadline: June 2, 2020
Class Period: common stock between February 8, 2019 and December 13, 2019 and/or who acquired Gossamer shares pursuant or traceable to Gossamer’s documents issued in connection with its February 8, 2019 initial public offering.
The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose: (1) the reasons for Gossamer’s GB001 trial failures; (2) the purported clinical validation of Novartis’ oral DP2 antagonist; and (3) that, as a result of the foregoing, Defendants’ public statements were materially false and misleading at all relevant times.
<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="eHealth, Inc. (EHTH)” data-reactid=”19″>eHealth, Inc. (EHTH)
<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/ehealth-inc-loss-submission-form?prid=6053&wire=1
Lead Plaintiff Deadline: June 8, 2020
Class Period: March 19, 2018 to April 7, 2020″ data-reactid=”20″>If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/ehealth-inc-loss-submission-form?prid=6053&wire=1
Lead Plaintiff Deadline: June 8, 2020
Class Period: March 19, 2018 to April 7, 2020
The complaint alleges that eHealth, Inc. issued materially false and/or misleading information and/or failed to disclose: (1) its highly aggressive accounting and modeling assumptions; (2) its skyrocketing rate of member churn, resulting from eHealth’s pursuit of low quality, lossmaking growth; (3) its reliance on direct response television advertising, which attracts an unprofitable, high churn enrollee; and (4) that as a result of the foregoing, defendants’ public statements were materially false and misleading at all relevant times.
<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="To learn more contact Vincent Wong, Esq. either via email [email protected] or by telephone at 212.425.1140.” data-reactid=”22″>To learn more contact Vincent Wong, Esq. either via email [email protected] or by telephone at 212.425.1140.
Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: [email protected]” data-reactid=”24″>CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: [email protected]
<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="SOURCE: The Law Offices of Vincent Wong” data-reactid=”25″>SOURCE: The Law Offices of Vincent Wong
View source version on accesswire.com:
https://www.accesswire.com/585501/SHAREHOLDER-ALERT-VMW-GOSS-EHTH-The-Law-Offices-of-Vincent-Wong-Reminds-Investors-of-Important-Class-Action-Deadlines
Add Comment